The global contract development and manufacturing organization (CDMO) sector is witnessing a significant shift toward securing domestic supply chains and expanding specialized production capabilities. In a major move that underscores this trend, Cambrex has officially broken ground on a massive expansion at its facility in Charles City, Iowa. The project represents a substantial investment in the infrastructure required for small molecule active pharmaceutical ingredients (APIs) and synthetic peptides.

This milestone is particularly symbolic as the Charles City facility celebrates its 100th anniversary. Marking a century of continuous operations, the site is positioning itself for future decades of pharmaceutical development and commercial-scale production.

A Century of Manufacturing: Cambrex Expands in Iowa

The groundbreaking ceremony, which took place on October 29, 2026, brought together a diverse group of stakeholders, including company executives, local employees, state and local officials, and members of the Charles City community. The event highlighted the deep-rooted history of the facility in the region and its evolving role in the global pharmaceutical supply chain.

The expansion project involves a total investment of $120 million. This capital injection will fund the construction and integration of new manufacturing infrastructure, which is anticipated to be completed in the fourth quarter of 2028. By expanding its footprint, Cambrex aims to address the growing demand for reliable, high-quality drug substance development and manufacturing services.

Strategic Capacity and Technical Capabilities

The core objective of the expansion is to significantly boost the site's manufacturing volume. The project will add 160,000 liters of capacity, representing an approximate increase of 25%. Once fully operational, this addition will bring the site's total capacity to nearly one million liters.

This expanded capacity is specifically designed to support:

  • The development of small molecule active pharmaceutical ingredients (APIs)
  • The commercial manufacturing of small molecule APIs
  • The synthesis and production of synthetic peptides
  • The manufacturing of pharmaceutical intermediates

By scaling up these capabilities, the Charles City facility will be equipped to support customer programs across their entire lifecycle, from early clinical development through to large-scale commercialization. The integration of synthetic peptide manufacturing alongside traditional small molecule APIs reflects a strategic alignment with modern therapeutic pipelines, which increasingly rely on complex molecules and specialized synthesis technologies.

Strengthening Domestic Pharmaceutical Supply Chains

The investment by Cambrex comes at a critical time for the pharmaceutical industry, where supply chain resilience and domestic manufacturing capabilities are highly prioritized. By expanding its operations in Iowa, Cambrex is reinforcing its commitment to U.S.-based manufacturing.

Claudio Russolo, the Chief Operating Officer and incoming Chief Executive Officer of Cambrex, emphasized the strategic importance of the project:

"This groundbreaking marks an important milestone in our continued investment in U.S. manufacturing and in the Charles City site. As the site celebrates its 100th anniversary, this expansion reflects both its long history and its continued importance to our future. By expanding commercial-scale capacity for both small molecule and peptide manufacturing, we are strengthening our ability to support customers as their programs advance from development through commercialization."

The ability to transition programs seamlessly from development to commercial-scale production within a single, highly regulated domestic site reduces logistical complexities and regulatory risks for pharmaceutical developers.

Collaborative Groundbreaking and Leadership Vision

The groundbreaking ceremony on October 29, 2026, featured key figures from both the public and private sectors, illustrating the collaborative effort required to execute large-scale industrial projects. Among the attendees were:

  • Joe Nettleton, Vice President of Operations and Site Leader for Cambrex Charles City
  • Timothy Fox, Chief Executive Officer of the Charles City Area Development Corporation
  • Senator Chuck Grassley of the United States Senate
  • Lieutenant Governor Chris Cournoyer of the State of Iowa
  • John Andrews, Vice President of Operations at Cambrex
  • Claudio Russolo, Chief Operating Officer and incoming Chief Executive Officer of Cambrex

The presence of high-ranking state and federal officials, including Senator Chuck Grassley and Lieutenant Governor Chris Cournoyer, underscores the economic and strategic significance of the Charles City facility to the state of Iowa and the broader national manufacturing landscape.

About Cambrex and Its Global Footprint

As a leading global CDMO, Cambrex brings over 45 years of experience to the pharmaceutical sector. The company employs a team of 2,000 experts who service a global client base from operations located across North America and Europe.

The organization offers a comprehensive suite of specialized drug substance technologies and analytical services, including:

  • Continuous flow manufacturing
  • Controlled substances handling
  • Peptide synthesis
  • Solid-state science
  • Biocatalysis
  • Material characterization
  • Complex synthetics production
  • Highly potent API (HPAPI) manufacturing

This extensive technological toolkit, combined with the massive capacity expansion in Charles City, positions Cambrex to remain a key partner for pharmaceutical and biotechnology companies worldwide as they navigate the complexities of drug substance development and commercialization.